Infectious Disease
Plasmodium Vivax Malaria
9
Pipeline Programs↗
1
Active Trials↗
5
Companies Involved↗
Plasmodium vivax malaria is an early-stage landscape with 9 programs across 5 companies. The most active players are Eastern Cooperative Oncology Group, Medicines for Malaria Venture, Glaxo Dba Glaxosmithkline. 2 therapies are approved with 4 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 34
Analysis
Trial Status
9
clinical trials
Completed6 · 67%
Terminated1 · 11%
Unknown status1 · 11%
Active, not recruiting1 · 11%
Clinical Trials
Trial Activity
9 trials
Efficacy of Focal Primaquine Mass Administration for Eliminating Plasmodium Vivax Malaria in Northern Myanmar
Active, not recruiting·—·N/A·NCT06392152·1,208 enrolled
Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria
Terminated·—·Phase 2·NCT02110784·27 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)